Showing results (111-120 of 129) with videos related to

Sort By:
Pageof 13
Viruses|July 28, 2026
Non-Canonical Binding of Nelfinavir in HIV-1 Protease Variants Reveals Structural Mechanisms of Antiretroviral ResistanceChristian Cadena-Cruz, Marcio De Avila-Arias, Fabio Guzmán, et al.
Journal of Cachexia, Sarcopenia and Muscle|February 22, 2018
Multiplatform plasma fingerprinting in cancer cachexia: a pilot observational and translational studyMónica Patricia Cala, María Teresa Agulló-Ortuño, Elena Prieto-García, et al.
Biomedicines|April 3, 2021
Tumor-Stromal Interactions in a Co-Culture Model of Human Pancreatic Adenocarcinoma Cells and Fibroblasts and Their Connection with Tumor SpreadElena Prieto-García, C Vanesa Díaz-García, Alba Agudo-López, et al.
BJU International|February 12, 2014
Impact of androgen suppression and zoledronic acid on bone mineral density and fractures in the Trans-Tasman Radiation Oncology Group (TROG) 03.04 Randomised Androgen Deprivation and Radiotherapy (RADAR) randomized controlled trial for locally advanced prostate cancerJames W Denham, Michael Nowitz, David Joseph, et al.
Alzheimer'S Research & Therapy|December 3, 2019
Plasma Aβ42/40 ratio alone or combined with FDG-PET can accurately predict amyloid-PET positivity: a cross-sectional analysis from the AB255 StudyVirginia Pérez-Grijalba, Javier Arbizu, Judith Romero, et al.
Leukemia & Lymphoma|February 1, 2011
Frontline treatment of follicular lymphoma with fludarabine, cyclophosphamide, and rituximab followed by rituximab maintenance: toxicities overcome its high antilymphoma effect. Results from a Spanish Cooperative Trial (LNHF-03)José Francisco Tomás, Carlos Montalbán, Alberto Fernández De Sevilla, et al.
Neurobiology of Disease|February 27, 2022
Cerebral metabolic pattern associated with progressive parkinsonism in non-human primates reveals early cortical hypometabolismFrancisco Molinet-Dronda, Javier Blesa, Natalia López-González Del Rey, et al.
Oncology and Therapy|December 12, 2022
Real-World Outcomes of Belantamab Mafodotin for Relapsed/Refractory Multiple Myeloma (RRMM): Preliminary Results of a Spanish Expanded Access Program (EAP)Adrián Alegre, Gonzalo Benzo, Rafael Alonso, et al.
Leukemia & Lymphoma|June 27, 2009
Influence of MBL-2 mutations in the infection risk of patients with follicular lymphoma treated with rituximab, fludarabine, and cyclophosphamideJoaquin Martínez-López, Ana Rivero, Inmaculada Rapado, et al.
Seminars in Hematology|December 4, 2018
Subcutaneous bortezomib in newly diagnosed patients with multiple myeloma nontransplant eligible: Retrospective evaluationFelipe de Arriba de la Fuente, Maria Soledad Durán, Miguel Ángel Álvarez, et al.
Pageof 13